A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer.

Carcinomas of the exocrine pancreas respond poorly to most chemotherapy regimens. Recently continuous infusional 5-fluorouracil (200 mg m-(2)day-1) with 3 weekly cisplatin (60 mg m-2) and epirubicin (50 mg m-2) (the ECF regimen) has proven to be an active regimen in gastric and breast cancer and con...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, T. R., Lofts, F. J., Mansi, J. L., Glees, J. P., Dalgleish, A. G., Knight, M. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1996
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074505/
https://www.ncbi.nlm.nih.gov/pubmed/8630289

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074505/
https://www.ncbi.nlm.nih.gov/pubmed/8630289

Ejemplares similares